alcaftadine

01/01/2019 - "Conclusion: Alcaftadine 0.25% is effective in preventing signs and symptoms of Japanese cedar pollen-induced allergic conjunctivitis."
11/17/2021 - ": Once-daily Alcaftadine 0.25% is safe and effective in preventing signs and symptoms of Japanese cedar-pollen allergic conjunctivitis."
11/17/2021 - "Efficacy of Alcaftadine 0.25% (AGN-229666) for Once-daily Prevention of Cedar-Pollen Allergic Conjunctivitis: A Phase 3 Randomized Study."
01/01/2022 - "In brief: OTC alcaftadine (Lastacaft Once Daily Relief) for allergic conjunctivitis."
11/17/2021 - "Purpose: This study evaluated the efficacy and safety of once-daily Alcaftadine 0.25% (AGN-229666) for prevention of signs and symptoms of Japanese cedar-pollen allergic conjunctivitis.Methods"

03/01/2011 - "Alcaftadine was effective in the prevention of ocular itching based on both clinically relevant and statistically significant differences compared with vehicle (placebo). "
11/17/2021 - "Alcaftadine 0.25% was statistically superior to vehicle for relief of ocular itching at 16 hours (p < .0001). "
07/01/2012 - "Alcaftadine is a safe and effective option for the prevention of ocular itching associated with allergic conjunctivitis, is dosed once daily, and is competitively priced among prescription medications for allergic conjunctivitis. "
07/01/2012 - "Two published clinical trials evaluated the efficacy of alcaftadine in the prevention of ocular itching and conjunctival redness associated with allergic conjunctivitis. "
07/01/2012 - "To evaluate the safety and efficacy of alcaftadine for the prevention of itching associated with allergic conjunctivitis. "

01/01/2023 - "Respondents were asked about the newer molecule (alcaftadine) and reservations regarding systemic immuno-suppressants and ordering allergy tests in their practice. "
03/01/2011 - "With an onset of action within 3 minutes and a duration of action of at least 16 hours, the statistically and clinically significant effect of alcaftadine 0.25% on itching make it an important addition to therapy for ocular allergy. "
01/01/2015 - "Histamine and the pathological mechanism of ocular allergy will be briefly reviewed with the intent of providing a background for the detailed discussion on the clinical utility of alcaftadine in allergic conjunctivitis. "

11/17/2021 - "Alcaftadine 0.25% was significantly better than vehicle for relief of conjunctival hyperemia. "
01/01/2019 - "Significantly lower hyperemia scores were observed in alcaftadine-treated than olopatadine-treated eyes at 7 and 15 min post-CAC (p ≤ 0.027). "
01/01/2019 - "Alcaftadine 0.25% (challenged 8 h post-dose) was significantly more effective than vehicle for prevention of itching and conjunctival hyperemia (p < 0.001) and noninferior to olopatadine 0.1% (challenged 4 h post-dose). "

07/24/2019 - "Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report."
07/24/2019 - "To report the first case of allergic contact dermatitis (ACD) associated with alcaftadine 0.25% ophthalmic solution. "